FLT3 (D835Y)
Sign in to save this workspaceFLT3 · Variant type: point · HGVS: p.D835Y
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Brigatinib | 99.9% | 0.1% | 82.96 |
| 2 | Pralsetinib | 99.6% | 0.4% | 93.43 |
| 3 | Sunitinib | 98.8% | 1.2% | 91.73 |
| 4 | Gilteritinib | 98.7% | 1.3% | 88.97 |
| 5 | Pacritinib | 98.7% | 1.3% | 88.64 |
| 6 | Fostamatinib | 98.1% | 1.9% | 96.74 |
| 7 | Entrectinib | 97.9% | 2.1% | 93.69 |
| 8 | Defactinib | 97.0% | 3.0% | 92.68 |
| 9 | Selpercatinib | 96.3% | 3.7% | 96.72 |
| 10 | Fedratinib | 96.2% | 3.8% | 96.21 |
| 11 | Avapritinib | 96.1% | 3.9% | 97.73 |
| 12 | Alectinib | 93.6% | 6.4% | 95.49 |
| 13 | Canertinib | 93.3% | 6.7% | 96.49 |
| 14 | Ponatinib | 92.5% | 7.5% | 78.23 |
| 15 | Nintedanib | 91.7% | 8.3% | 90.23 |
| 16 | Alpelisib | 88.5% | 11.5% | 97.22 |
| 17 | Tenalisib | 85.6% | 14.4% | 97.98 |
| 18 | Bosutinib | 82.2% | 17.8% | 87.22 |
| 19 | Dacomitinib | 80.9% | 19.1% | 97.99 |
| 20 | Rabusertib | 80.8% | 19.2% | 98.74 |
| 21 | Erlotinib | 80.2% | 19.8% | 99.75 |
| 22 | Pazopanib | 79.8% | 20.3% | 97.49 |
| 23 | Osimertinib | 79.3% | 20.7% | 97.24 |
| 24 | Quizartinib | 78.7% | 21.3% | 99.50 |
| 25 | Abemaciclib | 74.1% | 25.9% | 91.48 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Brigatinib | 99.9% | 98.1% | +1.8% |
| Pralsetinib | 99.6% | 97.6% | +2.0% |
| Sunitinib | 98.8% | 98.7% | +0.1% |
| Gilteritinib | 98.7% | 99.2% | -0.5% |
| Pacritinib | 98.7% | 93.6% | +5.1% |
| Fostamatinib | 98.1% | 97.2% | +0.9% |
| Entrectinib | 97.9% | 96.1% | +1.8% |
| Defactinib | 97.0% | 94.6% | +2.4% |
| Selpercatinib | 96.3% | 96.1% | +0.2% |
| Fedratinib | 96.2% | 98.2% | -1.9% |
| Avapritinib | 96.1% | 88.6% | +7.5% |
| Alectinib | 93.6% | 84.5% | +9.1% |
| Canertinib | 93.3% | 86.3% | +7.0% |
| Ponatinib | 92.5% | 97.9% | -5.4% |
| Nintedanib | 91.7% | 95.2% | -3.5% |
| Alpelisib | 88.5% | — | — |
| Tenalisib | 85.6% | — | — |
| Bosutinib | 82.2% | — | — |
| Dacomitinib | 80.9% | — | — |
| Rabusertib | 80.8% | — | — |
| Erlotinib | 80.2% | — | — |
| Pazopanib | 79.8% | — | — |
| Osimertinib | 79.3% | — | — |
| Quizartinib | 78.7% | 97.9% | -19.2% |
| Abemaciclib | 74.1% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| AML-US | Blood/Lymphatic System | ref |
| LAML-KR | Blood/Lymphatic System | ref |
| LAML-US | Blood/Lymphatic System | ref |
| LAML | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.8ms